BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-64@catalystbrief.girapphe.com
DTSTAMP:20261117T061553Z
LAST-MODIFIED:20261117T061553Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Pfizer — RSVpreF [Jan 2027]
DESCRIPTION:Phase 3 primary completion: Study to Evaluate the Efficacy\, Im
 munogenicity\, and Safety of RSVpreF in Adults..\nSource: https://clinical
 trials.gov/study/NCT05035212\nhttps://catalystbrief.girapphe.com/e/64?lang
 =en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/64?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
